Search Results for "corticosteroids"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for corticosteroids. Results 321 to 330 of 334 total matches.
Rosiglitazone/Glimepiride (Avandaryl) for Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006 (Issue 1230)
of
hyperglycemia, such as the thiazide diuretics and corticosteroids, may lead to loss of glycemic control ...
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved for patients already taking a combination of rosiglitazone and a sulfonylurea or those not adequately controlled on rosiglitazone or sulfonylurea monotherapy. Rosiglitazone is also available in a fixed-dose combination with metformin (Avandamet). Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms to control...
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
surgery
Corticosteroid
Dexamethasone – generic 4, 10 mg/mL vials and syringes 4-5 mg IV at induction ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
lung disease of prematurity who required
medical support (chronic corticosteroid therapy, diuretic ...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7 doi:10.58347/tml.2023.1685a | Show Introduction Hide Introduction
Drugs for Parasitic Infections
Treatment Guidelines from The Medical Letter • Aug 01, 2013 (Issue 143)
had failed PHMB, chlorhexidine and hexamidine.5,6 Use of corticosteroids
is controversial. Prolonged ...
With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians
anywhere may see infections caused by parasites. The table in this document lists first-choice and alternative drugs for most
parasitic infections.
Drugs for Tuberculosis
Treatment Guidelines from The Medical Letter • Apr 01, 2012 (Issue 116)
months and tuberculous meningitis for at least 9-12
months. Addition of a corticosteroid for 1-2 months ...
Tuberculosis (TB) is still a common cause of death
worldwide, and the prevalence of drug-resistant TB
poses challenges to its treatment and control.
Guidelines with detailed management recommendations
are available from the American Thoracic
Society, Centers for Disease Control and Prevention
(CDC) and Infectious Diseases Society of America
(IDSA).
Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
a salicylate long term
or a corticosteroid, or secondary cases within a household. Antiviral
treatment ...
The recommendations for treatment of varicella-zoster
virus (VZV) and herpes simplex virus (HSV)
infections are listed in tables 1 and 2. Vaccination
against VZV was reviewed in a previous issue.
Drugs for Thyroid Disorders
Treatment Guidelines from The Medical Letter • Aug 01, 2009 (Issue 84)
with Graves’ disease; pretreatment with corticosteroids may be helpful.
Some studies have shown a slight ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
.
12. Wait at least 1 month after discontinuing long-term administration of high-dose corticosteroids ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Chemotherapy for Esophageal, Gastric and Colorectal Cancers
Treatment Guidelines from The Medical Letter • Aug 01, 2006 (Issue 48)
with a corticosteroid can prevent or
mitigate the fluid retention syndrome and the hypersensitivity reactions ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.